Candidate gene and genome-wide association studies have not identified common variants, which are reliably associated with depression. The recent identification of obesity predisposing genes that are highly expressed in the brain raises the possibility of their genetic contribution to depression. As variation in the intron 1 of the fat mass-and obesity-associated (FTO) gene contributes to polygenic obesity, we assessed the possibility that FTO gene may contribute to depression in a cross-sectional multi-ethnic sample of 6561 depression cases and 21 932 controls selected from the EpiDREAM, INTERHEART, DeCC (depression case-control study) and Cohorte Lausannoise (CoLaus) studies. Major depression was defined according to DSM IV diagnostic criteria. Association analyses were performed under the additive genetic model. A meta-analysis of the four studies showed a significant inverse association between the obesity risk FTO rs9939609 A variant and depression (odds ratio ¼ 0.92 (0.89, 0.97), P ¼ 3 Â 10 À 4 ) adjusted for age, sex, ethnicity/population structure and body-mass index (BMI) with no significant between-study heterogeneity (I 2 ¼ 0%, P ¼ 0.63). The FTO rs9939609 A variant was also associated with increased BMI in the four studies (b 0.30 (0.08, 0.51), P ¼ 0.0064) adjusted for age, sex and ethnicity/population structure. In conclusion, we provide the first evidence that the FTO rs9939609 A variant may be associated with a lower risk of depression independently of its effect on BMI. This study highlights the potential importance of obesity predisposing genes on depression.
INTRODUCTION
Depression is a complex and prevalent psychiatric disorder that causes major personal, societal and economic consequences worldwide. 1, 2 Genetic susceptibility to depression was demonstrated through family and twin studies; 3 however, the contribution of specific genes remains largely inconclusive. 4 A candidate gene approach has mainly focused on neurotransmitters and was not able to find conclusive associations with depression. 5 Due to the recent success of genome-wide association studies to dissect complex traits, investigators in the depression field shifted from candidate gene to hypothesis-free approaches. Despite several genome-wide association studies including a recent meta-analysis of 16 023 cases of depression and 60 214 controls, the results have been disappointing with no signal reaching genome-wide evidence of significance. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] These data suggest that if common variants exist their effects are modest at best.
Currently, we have three approaches to search for genes associated with complex disorders such as depression: (1) the use of next generation sequencing technology to explore rare variants with stronger impact (rare variant common disease hypothesis); 16 (2) increase collaborative efforts to perform larger-scale genomewide association studies; and (3) use of innovative hypothesis driven approaches, which we have adopted in this study.
In 2007, four independent teams discovered that variation in the intron 1 of the fat mass-and obesity-associated (FTO) gene (rs9939609 polymorphism) is a major contributor to polygenic obesity in populations of European ancestry. [17] [18] [19] [20] Since these initial reports, the rs9939609 polymorphism has been consistently associated with obesity-related traits not only in Europeans but also in Chinese 21 South Asian Indian, 22 North American Indian, 23 South American 24 and African ethnicities. 25 Recently, studies suggested that depression may modify the effect of FTO intronic variants on body-mass index (BMI). 26 However, the potential effect of FTO gene variation on risk for depression has never been reported to date. Beyond the controversial association between obesity and depression, 27 additional arguments make the hypothesis that the FTO gene may be directly associated with depression plausible: (1) FTO is highly expressed in human brain, 18 (2) the FTO rs9939609 obesity risk variant is associated with structural brain atrophy and reduced verbal fluency in humans, 28,29 (3) complete FTO deficiency in humans induces a lethal syndrome characterized by microcephaly, structural brain malformations and functional brain deficits. 30 We sought to test the hypothesis that the FTO intron 1 gene variation is associated with depression using a cross-sectional design in a large multiethnic discovery sample and three independent replication samples totalling 6561 depression cases and 21 932 non-depressed controls from six ethnic backgrounds.
MATERIALS AND METHODS
We investigated the association between the common rs9939609 gene variant of FTO gene and depression in four independent samples. The study protocol has been approved by all local ethics committees and informed consent was obtained from each subject before participating in the study, in accordance with the Declaration of Helsinki.
EpiDREAM study
Sample selection. EpiDREAM is a prospective cohort study that enrolled 21 217 individuals who were at risk for type 2 diabetes recruited from 21 countries including subjects who participated in the DREAM trial. 31 The subjects were screened between 2001-2003. Detailed methods and description of the study cohort have been described earlier. 32 The current study used cross-sectional data from the baseline-screening visit for the EpiDREAM (n ¼ 16 716) and DREAM studies (n ¼ 4501). The study flow chart is illustrated in Supplementary Figure S1 . A total sample of 17 207 subjects issued from five ethnic groups (South Asian, European, African, Latin American and Native North American) and having both phenotypic and genotypic information available was included in this study.
Phenotype data. Demographic data as well as direct anthropometric measurements were obtained from study participants at baseline using a standardized protocol. The assessment of depression (a major depressive episode in the past 12 months) was performed using a structured case report form. Study participants were asked whether they have experienced any of the following symptoms during the past 12 months and whether these symptoms were persistent on a daily basis and lasted for at least 2 weeks: feeling sad, blue or depressed, loss of interest in most things, feeling tired or low energy, changing body weight, having difficulty sleeping, having difficulty concentrating, thinking about death and having low self-esteem or confidence (Supplementary Figure S3) . These questions were compiled to fulfil Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV) 33 diagnostic criteria for a depressive episode. A depressive episode was considered present if the individual had five or more of the above symptoms including depressed mood that were present for at least 2 weeks nearly every day for most of the day. Height and weight were measured at the time of the baseline interview.
Genotyping. DNA was collected from whole blood samples. The EpiDREAM genetic study began in 2007 and 19 197 samples have been genotyped using the Illumina 50K CVD Array. 34 We selected the common rs9939609 variant of FTO gene (call rate 96.3%) for this study. The rs9939609 polymorphism showed no deviation from Hardy-Weinberg equilibrium (HWE) in the five ethnic groups.
Replication studies INTERHEART study. INTERHEART was a standardized global case-control study (n ¼ 27 098) for myocardial infarction. The details of the study design and recruitment of participants were previously reported. 35 Subjects from four ethnicities (Europeans, South Asians, Chinese and Latin Americans) from the INTERHEART genetic study 36, 37 were included in the present analysis. The selection of the current sample is detailed in the INTEHEART study flow chart (Supplementary Figure S2) . The study participants were interviewed and provided data relating to demographic details, physical measurements (height and weight) and depressive symptoms according to DSM IV criteria for a major depressive episode in the previous 12 months using the same questionnaire as in EpiDREAM study. The current study subset was selected based on the availability of FTO genotype and depression data. Details of DNA extraction and genotyping have been previously published. 36, 37 Genotyping was performed using Sequenom panel for the European, South Asian and Latin American groups and a 96 single nucleotide polymorphism (SNP) panel using the Illumina Golden Gate technology for the Chinese. The call rate for the rs9939609 SNP was 95.5%. Deviation from HWE was assessed by analysing the genotypic distributions in controls only using an exact test within each of the four ethnicities using permutation (Po0.005). Test for HWE for rs9939609 showed no deviation from HWE in the selected ethnic groups.
The depression case-control study. The DeCC study is a multicentre study conducted over three investigative sites in London, Cardiff and Birmingham, UK. The aim of the study was to investigate genetic polymorphisms in subjects with recurrent depressive disorder compared with psychiatrically healthy controls. All study participants are of European descent. Detailed description of the study participants and methods were reported earlier. 38 Briefly, subjects who had experienced two or more episodes of depression were recruited from psychiatric outpatient clinics and hospitals (26%), general practice (46%) and through self-help groups and media advertisement (28%) during the years 2001-2004. Control subjects were recruited via the general practice based GENESiS study (GeneticEnvironmental Nature of Emotional States in Siblings) 39 and were included if they had no past or present psychiatric disorder. All study participants with recurrent depression were given a face-to-face semistructured diagnostic interview, the Schedule for Clinical Assessment in Neuropsychiatry (SCAN) 40 by trained interviewers to establish the diagnosis of recurrent depression. Potential control subjects were interviewed by telephone using the Past History Schedule 41 and were included if there was no evidence of past or present clinically significant psychiatric disorder. Height and weight were collected by self-report. DNA samples were obtained from whole blood or buccal epithelial cells for molecular genetic analysis as described earlier. 42 FTO rs9939609 was successfully imputed using the Beagle Program (BEAGLE Version 3.0 Copyright (c) 2007-2010 Brian L Browning), imputation r 2 ¼ 0.999 (using 2 genotyped SNPs (rs8050136, rs3751812)). The rs9939609 genotypic distribution followed HWE in controls (P ¼ 0.42).
CoLaus study. CoLaus was a population-based cohort study that assessed cardiometabolic risk factors in Lausanne, Switzerland. 43 The study also collected cross-sectional data relating to psychiatric disorders including depression. A lifetime diagnosis of depression was assigned based on DSM IV criteria and using the Diagnostic Interview for Genetic studies. 44 Cases of depression were compared with controls with no history of depression. Height and weight were measured at the time of interview. The full study description has been reported earlier. 43 Genotyping was performed using the Affymetrix 500K SNP chip (Affymetrix, Santa Clara, CA, USA). All study participants are of European descent.
Statistical analysis. Statistical power analyses were performed using QUANTO. 45 The EpiDREAM, INTERHEART, DeCC and CoLaus studies have a statistical power 480% to detect odds ratio (OR) as low as 1.12, 1.2, 1.2 and 1.19, respectively, at a level of 0.05 (two-sided). Statistical analyses were performed using SAS program version 9.1.3 (SAS Institute Inc., Cary, NC, USA). 46 In EpiDREAM, multivariable regression analysis was used to test the association between the SNP (using additive model) and depression unadjusted and adjusted for age, sex, ethnicity and BMI for the whole sample. Using multivariable analysis we also tested for the association between the rs9939609 variant and BMI. We examined residuals to assess model assumptions and we also checked possible collinearity between SNP and ethnicity using variance inflation factor (VIF), with VIF410 considered an indicator of strong colinearity. 47 We did not see any collinearity between the SNP and ethnicity (VIFo2). In order to know in this multi-ethnic sample whether the association between the rs9939609 variant and depression is ethnic specific or global, we explored possible interaction between rs9939609 SNP and ethnicity by including a genotype x ethnicity interaction term in the multivariable model. We also used the Cochran-Mantel-Haenszel test to compare the minor allele frequency (MAF) among ethnic groups simultaneously in cases and controls. Adjustment for diabetes status (EpiDREAM) or for myocardial infarction (INTERHEART) did not change the association results. Multivariable regression analysis was used in INTERHEART, DeCC and CoLaus studies to test the association between the SNP (additive model) and depression adjusting for age, sex, BMI and ethnicity (in INTERHEART) and population structure (in DeCC and CoLaus). For the meta-analyses, the generic inverse variance method and random-effects model were selected using review manager software (Revman, version 5.1, the Cochrane Collaboration, Oxford, England) and meta.summaries function of R RMETA package. 48 
RESULTS

EpiDREAM study
The population characteristics are presented in Table 1 . FTO rs9939609 genotype and allele frequencies by ethnic group are presented in Supplementary Table S1 . The A allele is the minor allele in all ethnic groups. As expected, the FTO rs9939609 A variant was associated with BMI (b ¼ 0.45 (0.33-0.57), P ¼ 2.3 Â 10 À 13 , adjusted for age, sex and ethnicity). These results show that each copy of the minor allele contributed to 0.45 unit increase of BMI. BMI was positively associated with depression (OR 1.02 (1.02-1.03), P ¼ 3.3 Â 10 À 11 adjusted for age, sex and ethnicity), indicating a modest increase in depression risk by 2% for each unit of BMI. The FTO obesity risk rs9939609 A variant was negatively associated with depression status (OR 0.94 (0.89-0.99), P ¼ 0.026 adjusted for age, sex and ethnicity) indicating that each copy of the minor allele reduced the risk of depression by 6%. After further adjustment for BMI the association between rs9939609 SNP and depression was slightly strengthened with each copy of the rs9939609 A variant being associated with 8% reduction in depression risk (OR 0.92 (0.87-0.98), P ¼ 0.0076 adjusted for age, sex, ethnicity and BMI). There was no significant interaction between ethnicity and the FTO variant on risk of depression (global interaction P ¼ 0.32). Supplementary  Table S5 . A directionally consistent non-significant association between the rs9939609 A variant and risk of depression was observed in this sample (OR 0.98 (0.88,1.09), P ¼ 0.75 adjusted for age, sex, population structure and BMI).
Replication studies
Meta-analyses.
A meta-analysis of the four studies, EpiDREAM, INTERHEART, DeCC and CoLaus, (total cases n ¼ 6561; total controls n ¼ 21 932) supported a significant protective effect of the FTO obesity risk rs9939609 A variant on depression adjusted for age, sex and ethnicity/population structure (OR 0.94 (0.90, 0.98), P ¼ 2 Â 10 À 3 ). Further adjustment for BMI modestly strengthened this protective effect (OR 0.92 (0.89, 0.97), P ¼ 3
). The unadjusted analysis showed a similar result. Overall, the meta-analysis results showed each copy of the rs9939609 A variant is associated with 8% reduction in depression risk.
As ORs may be overestimated in the discovery sample as a consequence of the 'Winner's curse' effect, 49 we assessed the association between the FTO SNP rs9939609 and depression risk in the INTERHEART, DeCC and CoLaus studies after removing the EpiDREAM discovery sample. The OR in the replication samples was similar in comparison with the OR estimated in the EpiDREAM discovery sample, and the association remained significant (OR 0.93 (0.87, 1.00) P ¼ 0.04, adjusted for age, sex, ethnicity and BMI, data not shown). Figure 1 illustrates the meta-analysis results of the four studies. There was no significant between-study heterogeneity as measured by the I 2 (I 2 ¼ 0%, P ¼ 0.63, Figure 1 ), confirming the consistency of the ORs.
We also performed meta-analysis restricted to European populations (data not shown) to confirm the association between the FTO SNP and depression is not restricted to nonEuropean populations. The results showed a directionally consistent non-significant association in European groups in the four studies (I 2 ¼ 0%, OR 0.96 (0.91, 1.01), P ¼ 0.11, adjusted for age, sex and BMI).
We replicated the association between FTO and BMI in these studies. rs9939609 A variant is associated with increased BMI (total effect b ¼ 0.30, (0.08,0.51), P ¼ 0.0064 adjusted for age, sex, ethnicity/population structure) with significant between-study heterogeneity (estimated heterogeneity variance: 0.037, P ¼ 0.001).
DISCUSSION
We demonstrated an inverse association between the FTO obesity risk rs9939609 A variant and major depression. Our study includes 6561 depression cases and 21 932 non-depressed controls, and is one of the larger case-control studies of depression reported to date. 14, 15, 50 The level of significance of this association in the meta-analysis (P ¼ 3 Â 10 À 4 ) is compelling in the context of a hypothesis-driven candidate gene and a single SNP study. We did not find any significant between-study heterogeneity in the metaanalysis, indicating that the magnitude of association between the rs9939609 A variant and depression is consistent among the four different studies (ORs varied from 0.89 to 0.98), despite the studies having different inclusion criteria and diverse ethnic composition. The interaction test between ethnicity and genotype on depression was non-significant in EpiDREAM and a trend of association was observed in INTERHEART, suggesting that ethnicity has no major impact on the magnitude of the association between FTO and depression.
The observation that FTO rs9939609 A variant is associated with a higher BMI but a lower risk of depression is unexpected and thus our result must be interpreted with caution. However, the fact that a directionally consistent protective effect of the rs9939609 A variant was found on depression in four studies (Figure 1 ) lends confidence that the result is not a random false-positive association. Our results are even further supported by a recent study by Lawlor et al. 51 in which the FTO rs9939609 variant was genotyped in 53 194 European adults from Copenhagen and a nominal association of the rs9939609 A variant was found with lower use of antidepressant medication (n ¼ 3109), a phenotype directly related to major depression status. The data from Lawlor et al. 51 however suggest that the links between the obesity predisposing gene and depression are complex. It is also important to consider that other factors influencing the association between FTO and depression remain unknown. However, the present study is an observational crosssectional study, which cannot explain the path of the observed association. Interestingly, we observed that the association of the FTO rs9939609 A variant with major depression status is not mediated by BMI. The association of the rs9939609 A variant with depression remains significant in the meta-analysis (OR 0.92 (0.89, 0.97), P ¼ 3 Â 10 À 4 ) after adjusting for BMI. Thus, our data suggest that FTO may have a broader role than initially thought, and may not only regulate energy balance and body weight but also have a direct impact on cognitive function and psychiatric disorders. The fact that FTO is highly expressed in human brain, 18 that the FTO rs9939609 obesity risk variant is associated with structural brain atrophy, verbal fluency, 28, 29 and psychological aspects of food behaviour like loss of control over eating 52 and that complete FTO deficiency in humans induces a lethal syndrome characterized by microcephaly, structural brain malformations and functional brain deficits 30 further supports a potential role of FTO in the control of emotion and behaviour. However, in addition to genetic association studies, biological analyses are needed to support a link between FTO and major depressive disorder.
The MAF of the FTO rs9939609 A variant is highly variable depending on the ethnic background, 17, [21] [22] [23] [24] [25] suggesting that the FTO locus may have undergone directional selection during human historical periods of erratic food supply.
53,54 Therefore, we investigated FTO rs9939609 MAF among the ethnic groups in our two multi-ethnic samples in cases and controls simultaneously in order to test whether there are differences in MAF among our different ethnic groups. The difference of the MAF among the ethnic groups are borderline significant in both multiethnic EpiDREAM and INTERHEART studies (P-values for the CochranMantel-Haenszel test are 0.059 in EpiDREAM and 0.063 in INTERHEART). The highest MAF of the FTO rs9939609 A allele was found in the African population (49.2%), whereas the lowest MAF was found in the Native North American population (23.1%) in the EpiDREAM sample, in line with previous observations in the literature. 21, 25 European, Latin American, South Asian Indian and Native North American populations had intermediary MAFs for the FTO rs9939609 A allele (MAF: 41.1%, 33.8%, 33.1% and 23.1% in the EpiDREAM sample, respectively). This variable allele frequency of the FTO rs9939609 A allele may have important consequences in terms of the prevented fraction of depression explained by the variant in different ethnic backgrounds. Starting from the observation that the OR of the FTO rs9939609 A variant for depression does not vary with ethnicity and using the OR value of 0.92 calculated in the meta-analysis, the presence of the FTO rs9939609 A variant is estimated to prevent 6.7% of major depression cases in the African population, 5.3% in Europeans, 4.5% in Latin Americans, 4.4% in South Asian Indians, 3.3% in Native North Americans and only 2.2% of major depression cases in the Chinese population. 
Strengths and limitations
Our study has a number of strengths including a large sample size, robust associations across multiple ethnic groups and reliable diagnosis of depression. In all four studies, the phenotypic assessment of depression cases and non-depressed control subjects was carefully performed. Major depression cases have been diagnosed based on the well-recognized Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV), 33 that occurred within the previous 12 months for EpiDREAM and INTERHEART studies and major life time episodes in DeCC and CoLaus studies. Control subjects were included in the DeCC study if they did not show evidence of a past or present clinically significant psychiatric disorder, and were 'psychiatrically healthy' and all the control participants in the CoLaus, EpiDREAM and INTERHEART studies were screened for depression and considered as controls if they did not fulfil the diagnostic criteria of major depression according to DSM IV. The major phenotypic difference among the three studies is that the DeCC study included cases of recurrent depressive disorder with at least two episodes of lifetime depression present, whereas EpiDREAM and INTERHEART cases included individuals with major depressive episode occurring within the previous 12 months and CoLaus study included individuals with lifetime diagnosis of depression. Our study has some limitations including the ascertainment of study participants (the sample included individuals at risk for diabetes, cases and controls for myocardial infarction, recurrent depression cases and a population cohort), lack of screening for other psychiatric disorders and the cross-sectional assessment of depression. In addition, we cannot totally exclude the possibility that unknown confounding factors may explain the association between the rs9939609 SNP in FTO gene and depression.
In summary, we provide the first evidence that an FTO obesity gene variant is associated with protection against major depression, independently of its effect on BMI. This suggests that the FTO gene may have a broader role than initially thought with an effect on depression and other common psychiatric disorders. This study also highlights the potential importance of studying the impact of obesity predisposing genes on depression.
